Tuesday, July 11, 2023
Zhejiang Doer Biologics has entered into a licence agreement with BioNTech. The agreement grants BioNTech a worldwide licence to utilise one of Doer Bio's innovative discoveries for the research, development, manufacturing, and commercialisation of biotherapeutics.
As part of the agreement, Doer Bio will receive an upfront payment from BioNTech and will also be eligible for potential milestone payments related to development, regulatory approval, and commercialisation.
This partnership with BioNTech is seen as a significant validation of Doer Bio's platform technologies, which have undergone extensive preclinical research and ongoing clinical studies. The collaboration between the two companies aims to translate Doer Bio's technologies and discoveries into novel therapies that can ultimately benefit patients worldwide.
This licence agreement represents an exciting opportunity for both Doer Bio and BioNTech to combine their expertise and resources to advance innovative biotherapeutics and make a positive impact on global healthcare.